Host-pathogen interaction in HIV infection

Current Opinion in Immunology

Volumn 25, Issue 4, 2013, Pages 463-469

  Chowdhury, Ankita ^a   Silvestri, Guido ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; CHEMOKINE RECEPTOR CCR5; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERFERON; NEUTRALIZING ANTIBODY; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; TRIPARTITE MOTIF PROTEIN 5; VIRUS ENVELOPE PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBODY RESPONSE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOMEGALOVIRUS; FOLLICULAR DENDRITIC CELL; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; INNATE IMMUNITY; INTERFERON PRODUCTION; LYMPHOID TISSUE; MEMORY T LYMPHOCYTE; MUCOSAL IMMUNITY; NONHUMAN; REVIEW; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; T LYMPHOCYTE ACTIVATION; VIREMIA; VIRUS CELL INTERACTION; VIRUS PATHOGENESIS; VIRUS REPLICATION;

AGING; ANIMALS; HIV; HIV INFECTIONS; HOST-PATHOGEN INTERACTIONS; HUMANS; VIRUS INTEGRATION; VIRUS REPLICATION;

EID: 84884147970     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2013.07.003     Document Type: Review

References (72)

1. Hatziioannou T., Evans D.T. Animal models for HIV/AIDS research. Nat Rev Microbiol 2012, 10:852-867.
2. Chahroudi A., Bosinger S.E., Vanderford T.H., Paiardini M., Silvestri M. Natural SIV hosts: showing AIDS the door. Science 2012, 335:1188-1193.
3. Okoye A.A., Rohankhedkar M., Abana C., Pattenn A., Reyes M., Pexton C., Lum R., Sylwester A., Planer S.L., Legasse A., et al. Naive T cells are dispensable for memory CD4+ T cell homeostasis in progressive simian immunodeficiency virus infection. J Exp Med 2012, 209:641-651.
4. Zhu J., Yamane H., Paul W.E. Differentiation of effector CD4T cell populations. Annu Rev Immunol 2010, 28:445-489.
5. Okoye A., Meier-Schellersheim M., Brenchley J.M., Hagen S.I., Walker J.M., Rohankhedkar M., Lum R., Edgar J.B., Planer S.L., Legasse A., et al. Progressive CD4+ central memory T cell decline results in CD4+ effector memory insufficiency and overt disease in chronic SIV infection. J Exp Med 2007, 204:2171-2185.
6. Brenchley J.M., Silvestri G., Douek D.C. Nonprogressive and progressive primate immunodeficiency lentivirus infections. Immunity 2010, 32:737-742.
7. + T cells are associated with limited CCR5 expression. Nat Med 2011, 17:830-836.
8. Brenchley J.M., Vinton C., Tabb B., Hao X.P., Connick E., Paiardini M., Lifson J.D., Silvestri G., Estes J.D. Differential infection patterns of CD4+ T cells and lymphoid tissue viral burden distinguish progressive and nonprogressive lentiviral infections. Blood 2012, 120:4172-4181.
9. Schmitz J.E., Ma Z.M., Hagan E.A., Wilks A.B., Furr K.L., Linde C.H., Zahn R.C., Brenchley J.M., Miller C.J., Permar S.R. Memory CD4(+) T lymphocytes in the gastrointestinal tract are a major source of cell-associated simian immunodeficiency virus in chronic nonpathogenic infection of African green monkeys. J Virol 2012, 86:11380-11385.
10. Descours B., Avettand-Fenoel V., Blanc C., Samri A., Mélard A., Supervie V., Theodorou I., Carcelain G., Rouzioux C., Autran B., et al. Immune responses driven by protective human leukocyte antigen alleles from long-term nonprogressors are associated with low HIV reservoir in central memory CD4 T cells. Clin Infect Dis 2012, 54:1495-1503.
11. Sáez-Cirión A., Bacchus C., Hocqueloux L., Avettand-Fenoel V., Girault I., Lecuroux C., Potard V., Versmisse P., Melard A., Prazuck T., et al. Post treatment HIV-1 controllers with a long-term virological remission after interruption of early initiated antiretroviral therapy ANRS VISCONTI study. PLOS Path 2013, 10.1371/journal.ppat.1003211.
12. Bieniasz P.D. An overview of intracellular interactions between immunodeficiency viruses and their hosts. AIDS 2012, 26:1243-1254.
13. Laguette N., Sobhian B., Casartelli N., Ringeard M., Chable-Bessia C., Ségéral E., Yatim A., Emiliani S., Schwartz O., Benkirane M. SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature 2011, 474:654-657.
14. Hrecka K., Hao C., Gierszewska M., Swanson S.K., Kesik-Brodacka M., Srivastava S., Florens L., Washburn M.P., Skowronski J. Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature 2011, 474:658-661.
15. Goldstone D.C., Ennis-Adeniran V., Hedden J.J., Groom H.C., Rice G.I., Christodoulou E., Walker P.A., Kelly G., Haire L.F., Yap M.W., et al. HIV-1 restriction factor SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase. Nature 2011, 480:379-382.
16. Lahouassa H., Daddacha W., Hofmann H., Ayinde D., Logue E.C., Dragin L., Bloch N., Maudet C., Bertrand M., Gramberg T. SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates. Nat Immunol 2012, 13:223-228.
17. Pertel T., Hausmann S., Morger D., Züger S., Guerra J., Lascano J., Reinhard C., Santoni F.A., Uchil P.D., Chatel L., et al. TRIM5 is an innate immune sensor for the retrovirus capsid lattice. Nature 2011, 472:361-365.
18. Galão R.P., Le Tortorec A., Pickering S., Kueck T., Neil S.J. Innate sensing of HIV-1 assembly by Tetherin induces NFκB-dependent proinflammatory responses. Cell Host Microbe 2012, 12:633-644.
19. Andrey T., Marissa S., Wilson K., Kathleen F., Rajendra S., John G. Stimulation of NF-κB Activity by the HIV Restriction Factor BST2. J Virol 2013, 87:2046-2057.
20. Norman J.M., Mashiba M., McNamara L.A., Onafuwa-Nuga A., Chiari-Fort E., Shen W., Collins K.L. The antiviral factor APOBEC3G enhances the recognition of HIV-infected primary T cells by natural killer cells. Nat Immunol 2011, 2:975-983.
21. Sodora D.L., Silvestri G. Immune activation and AIDS pathogenesis. AIDS 2008, 22:439-446.
22. Hunt P.W., Brenchley J., Sinclair E., McCune J.M., Roland M., Page-Shafer K., Hsue P., Emu B., Krone M., Lampiris H., et al. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis 2008, 197:126-133.
23. Choudhary S.K., Vrisekoop N., Jansen C.A., Otto S.A., Schuitemaker H., Miedema F., Camerini D. Low immune activation despite high levels of pathogenic human immunodeficiency virus type 1 results in long-term asymptomatic disease. J Virol 2007, 81:8838-8842.
24. Rotger M., Dalmau J., Rauch A., McLaren P., Bosinger S.E., Martinez R., Sandler N.G., Roque A., Liebner J., Battegay M., et al. Comparative transcriptomics of extreme phenotypes of human HIV-1 infection and SIV infection in sooty mangabey and rhesus macaque. J Clin Invest 2011, 121:2391-2400.
25. Bégaud E., Chartier L., Marechal V., Ipero J., Léal J., Versmisse P., Breton G., Fontanet A., Capoulade-Metay C., Fleury H., et al. Reduced CD4T cell activation and in vitro susceptibility to HIV-1 infection in exposed uninfected Central Africans. Retrovirology 2006, 3:35.
26. Songok E.M., Luo M., Liang B., Mclaren P., Kaefer N., Apidi W., Boucher G., Kimani J., Wachihi C., Sekaly R., et al. Microarray analysis of HIV resistant female sex workers reveal a gene expression signature pattern reminiscent of a lowered immune activation state. PLoS One 2012, 7:e30048.
27. Suy A., Castro P., Nomdedeu M., García F., López A., Fumero E., Gallart T., Lopalco L., Coll O., Gatell J.M., et al. Immunological profile of heterosexual highly HIV-exposed uninfected individuals: predominant role of CD4 and CD8 T-cell activation. J Infect Dis 2007, 196:1191-1201.
28. Naranbhai V., Abdool Karim S.S., Altfeld M., Samsunder N., Durgiah R., Sibeko S., Abdool Karim Q., Carr W.H., CAPRISA004 TRAPS team Innate immune activation enhances HIV acquisition in women, diminishing the effectiveness of tenofovir microbicide gel. J Infect Dis 2012, 206:993-1001.
29. Hong J.J., Amancha P.K., Rogers K., Ansari A.A., Villinger F. Spatial alterations between CD4(+) T follicular helper, B, and CD8(+) T cells during simian immunodeficiency virus infection: T/B cell homeostasis, activation, and potential mechanism for viral escape. J Immunol 2012, 188:3247-3256.
30. Petrovas C., Yamamoto T., Gerner M.Y., Boswell K.L., Wloka K., Smith E.C., Ambrozak D.R., Sandler N.G., Timmer K.J., Sun X., et al. CD4T follicular helper cell dynamics during SIV infection. J Clin Invest 2012, 122:3281-3294.
31. Perreau M., Savoye A.L., De Crignis E., Corpataux J.M., Cubas R., Haddad E.K., De Leval L., Graziosi C., Pantaleo G. Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production. J Exp Med 2013, 210:143-156.
32. Zeng M., Smith A.J., Wietgrefe S.W., Southern P.J., Schacker T.W., Reilly C.S., Estes J.D., Burton G.F., Silvestri G., Lifson J.D., et al. Cumulative mechanisms of lymphoid tissue fibrosis and T cell depletion in HIV-1 and SIV infections. J Clin Invest 2011, 121:998-1008.
33. Tabb B., Morcock D.R., Trubey C.M., Quiñones O.A., Hao X.P., Smedley J., Macallister R., Piatak M., Harris L.D., Paiardini M., et al. Reduced inflammation and lymphoid tissue immunopathology in rhesus macaques receiving anti-tumor necrosis factor treatment during primary simian immunodeficiency virus infection. J Infect Dis 2013, 207:880-892.
34. Brenchley J.M., Douek D.C. Microbial translocation across the GI tract. Annu Rev Immunol 2012, 30:149-173.
35. Handley S.A., Thackray L.B., Zhao G., Presti R., Miller A.D., Droit L., Abbink P., Maxfield L.F., Kambal A., Duan E., et al. Pathogenic simian immunodeficiency virus infection is associated with expansion of the enteric virome. Cell 2012, 151:253-266.
36. Klatt N.R., Canary L.A., Sun X., Vinton C.L., Funderburg N.T., Morcock D.R., Quiñones M., Deming C.B., Perkins M., Hazuda D.J., et al. Probiotic/prebiotic supplementation of antiretrovirals improves gastrointestinal immunity in SIV-infected macaques. J Clin Invest 2013, pii:66227.
37. Ortiz A.M., Klatt N.R., Li B., Yi Y., Tabb B., Hao X.P., Sternberg L., Lawson B., Carnathan P.M., Cramer E.M., et al. Depletion of CD4+ T cells abrogates post-peak decline of viremia in SIV-infected rhesus macaques. J Clin Invest 2011, 121:4433-4445.
38. Soghoian D.Z., Jessen H., Flanders M., Sierra-Davidson K., Cutler S., Pertel T., Ranasinghe S., Lindqvist M., Davis I., Lane K., et al. HIV-specific cytolytic CD4 T cell responses during acute HIV infection predict disease outcome. Sci Transi Med 2012, 4:123ra25.
39. Klatt NR, Silvestri G: CD4+ T cells and HIV: a paradoxical Pas de Deux. 4(123):123ps4.
40. Makedonas G., Betts M.R. Living in a house of cards: re-evaluating CD8+ T-cell immune correlates against HIV. Immunol Rev 2011, 239:109-124.
41. Fukazawa Y., Park H., Cameron M.J., Lefebvre F., Lum R., Coombes N., Mahyari E., Hagen S.I., Bae J.Y., Reyes M.D., et al. Lymph node T cell responses predict the efficacy of live attenuated SIV vaccines. Nat Med 2012, 18:1673-1681.
42. Hansen S.G., Ford J.C., Lewis M.S., Ventura A.B., Hughes C.M., Coyne-Johnson L., Whizin N., Oswald K., Shoemaker R., Swanson T., et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 2011, 473:523-527.
43. Mudd P.A., Martins M.A., Ericsen A.J., Tully D.C., Power K.A., Bean A.T., Piaskowski S.M., Duan L., Seese A., Gladden A.D., et al. Vaccine-induced CD8+ T cells control AIDS virus replication. Nature 2012, 491:129-133.
44. Scheid J.F., Mouquet H., Ueberheide B., Diskin R., Klein F., Oliveira T.Y., Pietzsch J., Fenyo D., Abadir A., Velinzon K., et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 2011, 333:1633-1637.
45. Wu X., Zhou T., Zhu J., Zhang B., Georgiev I., Wang C., Chen X., Longo N.S., Louder M., McKee K., et al. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 2011, 333:1593-1602.
46. Walker L.M., Huber M., Doores K.J., Falkowska E., Pejchal R., Julien J.P., Wang S.K., Ramos A., Chan-Hui P.Y., Moyle M., et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 2011, 477:466-470.
47. Pejchal R., Doores K.J., Walker L.M., Khayat R., Huang P.S., Wang S.K., Stanfield R.L., Julien J.P., Ramos A., Crispin M., et al. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 2011, 334:1097-1103.
48. McLellan J.S., Pancera M., Carrico C., Gorman J., Julien J.P., Khayat R., Louder R., Pejchal R., Sastry M., Dai K., et al. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 2011, 480:336-343.
49. Walker L.M., Sok D., Nishimura Y., Donau O., Sadjadpour R., Gautam R., Shingai M., Pejchal R., Ramos A., Simek M.D., et al. Rapid development of glycan-specific, broad, and potent anti-HIV-1 gp120 neutralizing antibodies in an R5 SIV/HIV chimeric virus infected macaque. Proc Natl Acad Sci 2011, 108:20125-20129.
50. Huang J., Ofek G., Laub L., Louder M.K., Doria-Rose N.A., Longo N.S., Imamichi H., Bailer R.T., Chakrabarti B., Sharma S.K., et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 2012, 491:406-412.
51. Hoot S., McGuire A.T., Cohen K.W., Strong R.K., Hangartner L., Klein F., Diskin R., Scheid J.F., Sather D.N., Burton D.R., et al. Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs. PLOS Pathog 2013, 9:e1003106.
52. Liao H.X., Lynch R., Zhou T., Gao F., Alam S.M., Boyd S.D., Fire A.Z., Roskin K.M., Schramm C.A., Zhang Z., et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 2013, 496:469-476.
53. Moore P.L., Gray E.S., Wibmer C.K., Bhiman J.N., Nonyane M., Sheward D.J., Hermanus T., Bajimaya S., Tumba N.L., Abrahams M.R., et al. Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. Nat Med. 2012, 18:1688-1692.
54. Mascola J.R., Stiegler G., VanCott T.C., Katinger H., Carpenter C.B., Hanson C.E., Beary H., Hayes D., Frankel S.S., Birx D.L., et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000, 6:207-210.
55. Hessel A.J., Hangartner L., Hunter M., Havenith C.E., Beurskens F.J., Bakker J.M., Lanigan C.M., Landucci G., Forthal D.N., Parren P.W., et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007, 449:101-105.
56. Moldt B., Rakasz E.G., Schultz N., Chan-Hui P.Y., Swiderek K., Weisgrau K.L., Piaskowski S.M., Bergman Z., Watkins D.I., Poignard P., et al. Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc Natl Acad Sci USA 2012, 109:18921-18925.
57. Jardine J., Julien J.P., Menis S., Ota T., Kalyuzhniy O., McGuire A., Sok D., Huang P.S., MacPherson S., Jones M., et al. Rational HIV immunogen design to target specific germline B cell receptors. Science 2013, 340:711-716.
58. Lindqvist M., van Lunzen J., Soghoian D.Z., Kuhl B.D., Ranasinghe S., Kranias G., Flanders M.D., Cutler S., Yudanin N., Muller M.I., et al. Expansion of HIV-specific T follicular helper cells in chronic HIV infection. J Clin Invest 2012, 122:3271-3280.
59. Cubas R.A., Mudd J.C., Savoye A.L., Perreau M., van Grevenynghe J., Metcalf T., Connick E., Meditz A., Freeman G.J., Abesada-Terk G., et al. Inadequate T follicular cell help impairs B cell immunity during HIV infection. Nat Med 2013, 19:494-499.
60. Herbeuval J.P., Nilsson J., Boasso A., Hardy A.W., Kruhlak M.J., Anderson S.A., Dolan M.J., Dy M., Andersson J., Shearer G.M. Differential expression of IFN-alpha and TRAIL/DR5 in lymphoid tissue of progressor versus nonprogressor HIV-1-infected patients. Proc Natl Acad Sci U S A 2006, 103:7000-7005.
61. Hyrcza M.D., Kovacs C., Loutfy M., Halpenny R., Heisler L., Yang S., Wilkins O., Ostrowski M., Der S.D. Distinct transcriptional profiles in ex vivo CD4+ and CD8+ T cells are established early in human immunodeficiency virus type 1 infection and are characterized by a chronic interferon response as well as extensive transcriptional changes in CD8+ T cells. J Virol 2007, 81:3477-3486.
62. Bosinger S.E., Li Q., Gordon S.N., Klatt N.R., Duan L., Xu L., Francella N., Sidahmed A., Smith A.J., Cramer E.M., et al. Global genomic analysis reveals rapid control of a robust innate response in SIV-infected sooty mangabeys. J Clin Invest 2009, 119:3556-3572.
63. Jacquelin B., Mayau V., Targat B., Liovat A.S., Kunkel D., Petitjean G., Dillies M.A., Roques P., Butor C., Silvestri G., et al. Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response. J Clin Invest 2009, 119:3544-3555.
64. Fernandez S., Tanaskovic S., Helbig K., Rajasuriar R., Kramski M., Murray J.M., Beard M., Purcell D., Lewin S.R., Price P., French M.A. CD4+ T-cell deficiency in HIV patients responding to antiretroviral therapy is associated with increased expression of interferon-stimulated genes in CD4+ T cells. J infect Dis 2011, 204:1927-1935.
65. Vanderford T.H., Slichter C., Rogers K.A., Lawson B.O., Obaede R., Else J., Villinger F., Bosinger S.E., Silvestri G. Treatment of SIV-infected sooty mangabeys with a type-I IFN agonist results in decreased virus replication without inducing hyperimmune activation. Blood 2012, 119:5750-5757.
66. Pillai S.K., Abdel-Mohsen M., Guatelli J., Skasko M., Monto A., Fujimoto K., Yukl S., Greene W.C., Kovari H., Rauch A., et al. Role of retroviral restriction factors in the interferon-α-mediated suppression of HIV-1 in vivo. Proc Natl Acad Sci U S A 2012, 109:3035-3040.
67. Azzoni L., Foulkes A.S., Papasavvas E., Mexas A.M., Lynn K.M., Mounzer K., Tebas P., Jacobson J.M., Frank I., Busch M.P., et al. Pegylated Interferon-α2A mono-therapy results in suppression of HIV-1 replication and decreased cell-associated HIV DNA integration. J Infect Dis 2013, 207:213-222.
68. Katlama C., Deeks S.G., Autran B., Martinez-Picado J., van Lunzen J., Rouzioux C., Miller M., Vella S., Schmitz J.E., Ahlers J., et al. Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. Lancet 2013, 381:2109-2117.
69. Hunt P.W. HIV and inflammation: mechanisms and consequences. Curr HIV/AIDS Rep 2012, 9:139-147.
70. Ganesan A., Crum-Cianflone N., Higgins J., Qin J., Rehm C., Metcalf J., Brandt C., Vita J., Decker C.F., Sklar P., et al. High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: results of a double-blind randomized placebo controlled clinical trial. J Infect Dis 2011, 203:756-764.
71. Piconi S., Parisotto S., Rizzardini G., Passerini S., Terzi R., Argenteri B., Meraviglia P., Capetti A., Biasin M., Trabattoni D., et al. Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders. Blood 2011, 118:3263-3272.
72. Deeks S.G., Autran B., Berkhout B., Benkirane M., Cairns S., Chomont N., Chun T.W., Churchill M., Di Mascio M., Katlama C., et al. Towards an HIV cure: a global scientific strategy. Nat Rev Immunol 2012, 12:607-614.